Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.41 |
| ▸ | SCN4A | P35499 | 4/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2716625 | 0.98 | CSNK2A1 (0.43) | CSNK2A1SCN4AHTR2AHTR2CHTR2B | |
| SCHEMBL18266460 | 0.89 | CSNK2A1 (0.41) | CSNK2A1SCN4AALOX15FFAR4 | |
| SCHEMBL19664434 | 0.87 | ALOX15 (0.40) | CSNK2A1SCN4AHTR2AHTR2CHTR2B | |
| SCHEMBL2715809 | 0.83 | KDM4E (0.39) | SCN4AFFAR4P2RX3S1PR1FFAR1 | |
| SCHEMBL2718192 | 0.83 | SCN4A (0.40) | SCN4AHTR2AHTR2CHTR2BREN | |
| SCHEMBL4550723 | 0.82 | KDM4E (0.49) | CSNK2A1HTR2AHTR2CHTR2B | |
| SCHEMBL4550404 | 0.81 | CSNK2A1 (0.39) | CSNK2A1HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL2714173 | 0.81 | KDM4E (0.47) | CSNK2A1HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL2715847 | 0.80 | HTR2A (0.41) | CSNK2A1HTR2AHTR2CHTR2B | |
| SCHEMBL4550411 | 0.80 | CSNK2A1 (0.59) | CSNK2A1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630122-B1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN2B, SCN1B, SCN2A | CSNK2A1 2688/4885SCN4A 20/4885HTR2A 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.